Loading clinical trials...
Loading clinical trials...
An Open Label Study Examining the Efficacy and Cardiovascular Risk of Immediate Versus Deferred Switch From a Boosted PI to Dolutegravir (DTG) in HIV Infected Patients With Stable Virological Suppression
Conditions
Interventions
Dolutegravir
Locations
33
Belgium
Insititute Of Tropical Medicine Antwerp
Antwerp, Belgium
CHU Saint-Pierre
Brussels, Belgium
Universitaire Ziekenhuis Gent
Ghent, Belgium
Hopital de la Croix Rousse
Lyon, France
Service des Maladies Infectieuses et Tropicales du CHU de NANTES
Nantes, France
Hopital Saint Louis
Paris, France
Start Date
April 1, 2014
Primary Completion Date
November 1, 2017
Completion Date
December 4, 2017
Last Updated
April 9, 2018
NCT07071623
NCT04929028
NCT01875588
NCT03087253
NCT07199335
NCT05419024
Lead Sponsor
St Stephens Aids Trust
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions